Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
NYSE:SNY's Cash to Debt is ranked higher than
98% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. NYSE:SNY: No Debt )
NYSE:SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Interest Coverage 8.34
NYSE:SNY's Interest Coverage is ranked higher than
57% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 203.80 vs. NYSE:SNY: 8.34 )
NYSE:SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 8.34

7.88
19.65
WACC vs ROIC
6.73%
14.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 17.28
NYSE:SNY's Operating margin (%) is ranked higher than
87% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.33 vs. NYSE:SNY: 17.28 )
NYSE:SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 17.28

15.25
38.21
Net-margin (%) 12.27
NYSE:SNY's Net-margin (%) is ranked higher than
84% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. NYSE:SNY: 12.27 )
NYSE:SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.27

7.92
25.8
ROE (%) 14.97
NYSE:SNY's ROE (%) is ranked higher than
89% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NYSE:SNY: 14.97 )
NYSE:SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 14.97

5.18
33.55
ROA (%) 8.68
NYSE:SNY's ROA (%) is ranked higher than
88% of the 912 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.12 vs. NYSE:SNY: 8.68 )
NYSE:SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 8.68

2.62
21.59
ROC (Joel Greenblatt) (%) 69.54
NYSE:SNY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.05 vs. NYSE:SNY: 69.54 )
NYSE:SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.28   Max: 145.55
Current: 69.54

31.28
145.55
Revenue Growth (3Y)(%) 0.50
NYSE:SNY's Revenue Growth (3Y)(%) is ranked higher than
63% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. NYSE:SNY: 0.50 )
NYSE:SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.5   Max: 27.4
Current: 0.5

0.5
27.4
EBITDA Growth (3Y)(%) -2.00
NYSE:SNY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NYSE:SNY: -2.00 )
NYSE:SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -2   Max: 35.9
Current: -2

-2
35.9
EPS Growth (3Y)(%) -10.50
NYSE:SNY's EPS Growth (3Y)(%) is ranked higher than
66% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. NYSE:SNY: -10.50 )
NYSE:SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -11.5   Max: 41.7
Current: -10.5

-11.5
41.7
» NYSE:SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNY Guru Trades in Q1 2014

Steven Cohen 300,000 sh (New)
Scott Black 247,100 sh (New)
Bill Nygren 2,600,000 sh (New)
John Buckingham 20,080 sh (New)
Manning & Napier Advisors, Inc 2,923,087 sh (+836.86%)
HOTCHKIS & WILEY 9,804,594 sh (+65.83%)
James Barrow 27,790,116 sh (+22.72%)
Sarah Ketterer 506,901 sh (+17.52%)
PRIMECAP Management 2,476,856 sh (+8.58%)
Charles Brandes 2,072,790 sh (+2.95%)
Ken Fisher 12,926,402 sh (+0.84%)
Dodge & Cox 43,664,887 sh (+0.08%)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
John Hussman 22,100 sh (unchged)
Third Avenue Management 15,706 sh (-2.48%)
NWQ Managers 5,460,055 sh (-6.39%)
Jean-Marie Eveillard 610,749 sh (-6.68%)
» More
Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.3%)
Ken Fisher 13,079,575 sh (+1.18%)
Murray Stahl 26,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
Jean-Marie Eveillard 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

Ken Fisher 13,085,033 sh (-0.46%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Bill Nygren 2014-09-30 Add 14.55%0.27%$50.89 - $57.29 $ 46.09-14%5670000
Jean-Marie Eveillard 2014-09-30 Reduce -94.39%0.07%$50.89 - $57.29 $ 46.09-14%34157
PRIMECAP Management 2014-09-30 Add 29.21%0.05%$50.89 - $57.29 $ 46.09-14%3891356
NWQ Managers 2014-06-30 Reduce -52.34%1.31%$51.23 - $54.54 $ 46.09-13%2602503
Bill Nygren 2014-06-30 Add 90.38%0.9%$51.23 - $54.54 $ 46.09-13%4950000
Scott Black 2014-06-30 Reduce -27.57%0.39%$51.23 - $54.54 $ 46.09-13%178985
John Hussman 2014-06-30 Sold Out 0.09%$51.23 - $54.54 $ 46.09-13%0
PRIMECAP Management 2014-06-30 Add 21.59%0.03%$51.23 - $54.54 $ 46.09-13%3011646
Scott Black 2014-03-31 New Buy1.4%$47.77 - $53.63 $ 46.09-9%247100
Bill Nygren 2014-03-31 New Buy1.1%$47.77 - $53.63 $ 46.09-9%2600000
HOTCHKIS & WILEY 2014-03-31 Add 65.83%0.75%$47.77 - $53.63 $ 46.09-9%9804594
James Barrow 2014-03-31 Add 22.72%0.39%$47.77 - $53.63 $ 46.09-9%27790116
NWQ Managers 2014-03-31 Reduce -6.39%0.17%$47.77 - $53.63 $ 46.09-9%5460055
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.40
NYSE:SNY's P/E(ttm) is ranked higher than
84% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.10 vs. NYSE:SNY: 26.40 )
NYSE:SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 402.35
Current: 26.4

9.64
402.35
Forward P/E 27.17
NYSE:SNY's Forward P/E is ranked higher than
83% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.61 vs. NYSE:SNY: 27.17 )
N/A
PE(NRI) 26.40
NYSE:SNY's PE(NRI) is ranked higher than
84% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.10 vs. NYSE:SNY: 26.40 )
NYSE:SNY' s 10-Year PE(NRI) Range
Min: 9.97   Max: 428.21
Current: 26.4

9.97
428.21
P/S 3.25
NYSE:SNY's P/S is ranked higher than
76% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.97 vs. NYSE:SNY: 3.25 )
NYSE:SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.22
Current: 3.25

1.77
5.22
PFCF 14.59
NYSE:SNY's PFCF is ranked higher than
96% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NYSE:SNY: 14.59 )
NYSE:SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45.57
Current: 14.59

5.11
45.57
POCF 11.48
NYSE:SNY's POCF is ranked higher than
93% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.14 vs. NYSE:SNY: 11.48 )
NYSE:SNY' s 10-Year POCF Range
Min: 4.15   Max: 23.75
Current: 11.48

4.15
23.75
EV-to-EBIT 18.72
NYSE:SNY's EV-to-EBIT is ranked higher than
87% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.50 vs. NYSE:SNY: 18.72 )
NYSE:SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 18.72

10.5
204.2
Shiller P/E 23.41
NYSE:SNY's Shiller P/E is ranked higher than
90% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 229.54 vs. NYSE:SNY: 23.41 )
NYSE:SNY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 25.36
Current: 23.41

13.35
25.36
Days Inventory 163.62
NYSE:SNY's Days Inventory is ranked higher than
68% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 149.40 vs. NYSE:SNY: 163.62 )
NYSE:SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 163.62

155.87
224.59
Days Sales Outstanding 77.80
NYSE:SNY's Days Sales Outstanding is ranked higher than
76% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.21 vs. NYSE:SNY: 77.80 )
NYSE:SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 77.8

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.14
NYSE:SNY's Dividend Yield is ranked higher than
95% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. NYSE:SNY: 4.14 )
NYSE:SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 4.14

1.41
5.46
Dividend Payout 0.90
NYSE:SNY's Dividend Payout is ranked higher than
69% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.63 vs. NYSE:SNY: 0.90 )
NYSE:SNY' s 10-Year Dividend Payout Range
Min: 1.17   Max: 8.47
Current: 0.9

1.17
8.47
Dividend growth (3y) 4.90
NYSE:SNY's Dividend growth (3y) is ranked higher than
79% of the 340 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. NYSE:SNY: 4.90 )
NYSE:SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: 4.9

0
22.1
Yield on cost (5-Year) 5.57
NYSE:SNY's Yield on cost (5-Year) is ranked higher than
93% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. NYSE:SNY: 5.57 )
NYSE:SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.87   Max: 7.24
Current: 5.57

1.87
7.24
Share Buyback Rate -0.80
NYSE:SNY's Share Buyback Rate is ranked higher than
76% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.10 vs. NYSE:SNY: -0.80 )
NYSE:SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.16
NYSE:SNY's Price/DCF (Projected) is ranked higher than
94% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.94 vs. NYSE:SNY: 1.16 )
NYSE:SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 5.65
Current: 1.16

0.48
5.65
Price/Median PS Value 1.13
NYSE:SNY's Price/Median PS Value is ranked higher than
78% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. NYSE:SNY: 1.13 )
NYSE:SNY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 8.59
Current: 1.13

0.64
8.59
Earnings Yield (Greenblatt) 5.30
NYSE:SNY's Earnings Yield (Greenblatt) is ranked higher than
86% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NYSE:SNY: 5.30 )
NYSE:SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 5.3

0.5
9.5
Forward Rate of Return (Yacktman) 2.99
NYSE:SNY's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. NYSE:SNY: 2.99 )
NYSE:SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.3   Max: 59.3
Current: 2.99

2.3
59.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK